<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03239704</url>
  </required_header>
  <id_info>
    <org_study_id>URGENT-IBD</org_study_id>
    <nct_id>NCT03239704</nct_id>
  </id_info>
  <brief_title>Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease</brief_title>
  <official_title>Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease (URGENT-IBD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crohn's and Colitis Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory Bowel Diseases (IBD) refers to a category of disorders, consisting of Crohn's&#xD;
      Disease (CD) and Ulcerative Colitis (UC), where segments of the gastrointestinal tract become&#xD;
      inflamed and ulcerated. Canada has among the highest incidence rates of IBD in the world -&#xD;
      16.3 and 12.3 per 100,000 for CD and UC respectively. In the absence of a cure, the current&#xD;
      goal of treatment is to manage patients in a milder state of remission. However, maintaining&#xD;
      (or even achieving) remission is dependent on timely access to specialist IBD care; which in&#xD;
      light of rising incidence rates have proven to be challenging. Moreover, patients often&#xD;
      experience flare-ups of their gastrointestinal symptoms, while awaiting access to specialist&#xD;
      care. In recent years, there has been increased integration of telemedicine services in&#xD;
      gastroenterology practice. This change has been driven by a desire among IBD patients to have&#xD;
      more flexible follow-up care, where 'virtual' care is provided as an adjunct to in-person&#xD;
      consultations. Within the context of IBD, telemedicine might be effective in delivering&#xD;
      routine and timely follow-up care to high-risk patients. The purpose of this study to&#xD;
      determine whether telemedicine-based follow-up care can effectively manage the&#xD;
      gastrointestinal symptoms of high-risk IBD patients and reduce their need for preventive&#xD;
      health care services.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory Bowel Diseases (IBD) refers to a category of disorders, consisting of Crohn's&#xD;
      Disease (CD) and Ulcerative Colitis (UC), where segments of the gastrointestinal tract become&#xD;
      inflamed and ulcerated. Canada has among the highest incidence rates of IBD in the world -&#xD;
      16.3 and 12.3 per 100,000 for CD and UC respectively. Moreover, IBD care spans a broad range&#xD;
      of inpatient, outpatient, and emergency services; which vary across populations due to the&#xD;
      heterogeneous nature of these conditions. The economic burden of IBD in Canada is estimated&#xD;
      to be $2.8 billion per anum, where direct health care costs (i.e. medications,&#xD;
      hospitalizations, physician visits) alone exceed $1.2 billion.&#xD;
&#xD;
      In the absence of a cure, the current goal of treatment is to manage patients in a milder&#xD;
      state of remission. However, maintaining (or even achieving) remission is dependent on timely&#xD;
      access to specialist IBD care; which in light of rising incidence rates have proven to be&#xD;
      challenging. Wait times for gastroenterology care are currently in excess of guidelines&#xD;
      outlined by the Canadian Association of Gastroenterology - Wait Times Consensus Group.&#xD;
      Moreover, patients often experience flare-ups of their gastrointestinal symptoms, while&#xD;
      awaiting access to specialist care.&#xD;
&#xD;
      In recent years, there has been increased integration of telemedicine services in&#xD;
      gastroenterology practice. This change has been driven by a desire among IBD patients to have&#xD;
      more flexible follow-up care, where 'virtual' care is provided as an adjunct to in-person&#xD;
      consultations. Telemedicine is the process by which medical information is transferred&#xD;
      between providers and patients through an electronic interface (i.e. two-way video,&#xD;
      smartphone applications and secure messaging). Within the context of IBD, telemedicine might&#xD;
      be effective in delivering routine and timely follow-up care to high-risk patients. It's also&#xD;
      enticing to speculate that if telemedicine follow-up care can adequately manage the&#xD;
      gastrointestinal symptoms of high-risk patients, then it may also reduce their need for&#xD;
      preventive health care services and alleviate some of the economic burden associated with&#xD;
      these conditions.&#xD;
&#xD;
      Therefore, the purpose of this study to determine whether telemedicine-based follow-up care&#xD;
      can effectively manage the gastrointestinal symptoms of high-risk IBD patients and reduce&#xD;
      their need for preventive health care services. As part of this study, we will attempt to&#xD;
      recruit all IBD outpatients, who were seen at the Mount Sinai Hospital urgent care clinic.&#xD;
      These are a subset of high-risk IBD patients, who often have moderate to severe exacerbations&#xD;
      of their medical condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Appointment IBD related Hospital Admission</measure>
    <time_frame>Within 30 days of study enrolment</time_frame>
    <description>Incidence of post-appointment IBD related hospital admission will be recorded for all patients enrolled in the study. Post-appointment hospital admissions will be defined as any IBD related hospital admission following the initial urgent care clinic appointment when the patient was enrolled in the study. Post-appointment IBD related hospital admission rates will will be compared between study groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-Appointment IBD related Surgery</measure>
    <time_frame>Within 30 days of study enrolment</time_frame>
    <description>Incidence of post-appointment IBD related surgery will be recorded for all patients enrolled in the study. Post-appointment IBD related surgery will be defined as any IBD related surgery following the initial urgent care clinic appointment when the patient was enrolled in the study. Post-appointment IBD related surgery rates will be compared between compared study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction with Health Care in IBD</measure>
    <time_frame>At 30 days following study enrolment</time_frame>
    <description>Patient satisfaction with health care in IBD as measured by CACHE will be collected from all patients, through a web-based questionnaire administered at 30 days following the initial urgent care clinic appointment, where the patient was enrolled in the study. Mean scores for Patient Satisfaction with Health Care in IBD will be compared between study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBD related Quality of Life</measure>
    <time_frame>At 30 days following study enrolment</time_frame>
    <description>IBD related Quality of Life as measured by IBDQ will be collected from all patients, through a web-based questionnaire administered at 30 days following the initial urgent care clinic appointment, where the patient was enrolled in the study. Mean scores for IBD related Quality of Life will be be compared between study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity</measure>
    <time_frame>At 30 days following study enrolment</time_frame>
    <description>Disease Activity as measured by PRO-2 score for Crohn's Disease or the 6-Point Mayo score for Ulcerative Colitis will be collected from all patients, through a web-based questionnaire administered at 30 days following the initial urgent care clinic appointment where the patient was enrolled in the study. Mean scores for disease activity will be compared between study groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Telemedicine Follow-Up and Telemedicine Monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telemedicine Follow-Up</intervention_name>
    <description>Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.</description>
    <arm_group_label>Telemedicine Follow-Up and Telemedicine Monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telemedicine Monitoring</intervention_name>
    <description>Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.</description>
    <arm_group_label>Telemedicine Follow-Up and Telemedicine Monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>30 Day Comprehensive Questionnaire</intervention_name>
    <description>Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.</description>
    <arm_group_label>Minimal Intervention</arm_group_label>
    <arm_group_label>Telemedicine Follow-Up and Telemedicine Monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Confirmed diagnosis of Crohn's Disease or Ulcerative Colitis&#xD;
&#xD;
          -  Recruited from an IBD urgent care clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who can't communicate in English&#xD;
&#xD;
          -  Subjects who are read or write in English&#xD;
&#xD;
          -  Subjects who lack internet access&#xD;
&#xD;
          -  Subjects who lack access to a personal smartphone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey C Nguyen</last_name>
    <role>Principal Investigator</role>
    <affiliation>MOUNT SINAI HOSPITAL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geoffrey C Nguyen, MD, PhD</last_name>
    <phone>416-586-4800</phone>
    <phone_ext>2819</phone_ext>
    <email>geoff.nguyen@utoronto.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Geoffrey C Nguyen, MD, PhD</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>2819</phone_ext>
      <email>geoff.nguyen@utoronto.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, Glasgow KW, Fernandes A, Ghosh S. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012 Nov;26(11):811-7. doi: 10.1155/2012/984575.</citation>
    <PMID>23166905</PMID>
  </reference>
  <reference>
    <citation>Park MD, Bhattacharya J, Park K. Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting. PeerJ. 2014 Sep 23;2:e587. doi: 10.7717/peerj.587. eCollection 2014.</citation>
    <PMID>25279267</PMID>
  </reference>
  <reference>
    <citation>Novak K, Veldhuyzen Van Zanten S, Pendharkar SR. Improving access in gastroenterology: the single point of entry model for referrals. Can J Gastroenterol. 2013 Nov;27(11):633-5. doi: 10.1155/2013/519342. Epub 2013 Sep 13.</citation>
    <PMID>24040629</PMID>
  </reference>
  <reference>
    <citation>Paterson WG, Depew WT, Pare P, Petrunia D, Switzer C, Veldhuyzen van Zanten SJ, Daniels S; Canadian Association of Gastroenterology Wait Time Consensus Group. Canadian consensus on medically acceptable wait times for digestive health care. Can J Gastroenterol. 2006 Jun;20(6):411-23. doi: 10.1155/2006/343686.</citation>
    <PMID>16779459</PMID>
  </reference>
  <reference>
    <citation>Paterson WG, Barkun AN, Hopman WM, Leddin DJ, Pare P, Petrunia DM, Sewitch MJ, Switzer C, van Zanten SV. Wait times for gastroenterology consultation in Canada: the patients' perspective. Can J Gastroenterol. 2010 Jan;24(1):28-32. doi: 10.1155/2010/912970.</citation>
    <PMID>20186353</PMID>
  </reference>
  <reference>
    <citation>Cross RK, Kane S. Integration of Telemedicine Into Clinical Gastroenterology and Hepatology Practice. Clin Gastroenterol Hepatol. 2017 Feb;15(2):175-181. doi: 10.1016/j.cgh.2016.09.011. Epub 2016 Dec 16. No abstract available.</citation>
    <PMID>27989663</PMID>
  </reference>
  <reference>
    <citation>Kemp K, Griffiths J, Campbell S, Lovell K. An exploration of the follow-up up needs of patients with inflammatory bowel disease. J Crohns Colitis. 2013 Oct;7(9):e386-95. doi: 10.1016/j.crohns.2013.03.001. Epub 2013 Mar 27.</citation>
    <PMID>23541150</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Crohn Disease</keyword>
  <keyword>Quality Improvement</keyword>
  <keyword>Telemedicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03239704
org study id: URGENT-IBD
nct id: NCT03239704
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Inflammatory Bowel Diseases (IBD) refers to a category of disorders, consisting of Crohn's
      Disease (CD) and Ulcerative Colitis (UC), where segments of the gastrointestinal tract become
      inflamed and ulcerated. Canada has among the highest incidence rates of IBD in the world -
      16.3 and 12.3 per 100,000 for CD and UC respectively. In the absence of a cure, the current
      goal of treatment is to manage patients in a milder state of remission. However, maintaining
      (or even achieving) remission is dependent on timely access to specialist IBD care; which in
      light of rising incidence rates have proven to be challenging. Moreover, patients often
      experience flare-ups of their gastrointestinal symptoms, while awaiting access to specialist
      care. In recent years, there has been increased integration of telemedicine services in
      gastroenterology practice. This change has been driven by a desire among IBD patients to have
      more flexible follow-up care, where 'virtual' care is provided as an adjunct to in-person
      consultations. Within the context of IBD, telemedicine might be effective in delivering
      routine and timely follow-up care to high-risk patients. The purpose of this study to
      determine whether telemedicine-based follow-up care can effectively manage the
      gastrointestinal symptoms of high-risk IBD patients and reduce their need for preventive
      health care services.
Inflammatory Bowel Diseases (IBD) refers to a category of disorders, consisting of Crohn's
      Disease (CD) and Ulcerative Colitis (UC), where segments of the gastrointestinal tract become
      inflamed and ulcerated. Canada has among the highest incidence rates of IBD in the world -
      16.3 and 12.3 per 100,000 for CD and UC respectively. Moreover, IBD care spans a broad range
      of inpatient, outpatient, and emergency services; which vary across populations due to the
      heterogeneous nature of these conditions. The economic burden of IBD in Canada is estimated
      to be $2.8 billion per anum, where direct health care costs (i.e. medications,
      hospitalizations, physician visits) alone exceed $1.2 billion.

      In the absence of a cure, the current goal of treatment is to manage patients in a milder
      state of remission. However, maintaining (or even achieving) remission is dependent on timely
      access to specialist IBD care; which in light of rising incidence rates have proven to be
      challenging. Wait times for gastroenterology care are currently in excess of guidelines
      outlined by the Canadian Association of Gastroenterology - Wait Times Consensus Group.
      Moreover, patients often experience flare-ups of their gastrointestinal symptoms, while
      awaiting access to specialist care.

      In recent years, there has been increased integration of telemedicine services in
      gastroenterology practice. This change has been driven by a desire among IBD patients to have
      more flexible follow-up care, where 'virtual' care is provided as an adjunct to in-person
      consultations. Telemedicine is the process by which medical information is transferred
      between providers and patients through an electronic interface (i.e. two-way video,
      smartphone applications and secure messaging). Within the context of IBD, telemedicine might
      be effective in delivering routine and timely follow-up care to high-risk patients. It's also
      enticing to speculate that if telemedicine follow-up care can adequately manage the
      gastrointestinal symptoms of high-risk patients, then it may also reduce their need for
      preventive health care services and alleviate some of the economic burden associated with
      these conditions.

      Therefore, the purpose of this study to determine whether telemedicine-based follow-up care
      can effectively manage the gastrointestinal symptoms of high-risk IBD patients and reduce
      their need for preventive health care services. As part of this study, we will attempt to
      recruit all IBD outpatients, who were seen at the Mount Sinai Hospital urgent care clinic.
      These are a subset of high-risk IBD patients, who often have moderate to severe exacerbations
      of their medical condition.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Health Services Research
masking: None (Open Label)
measure: Post-Appointment IBD related Hospital Admission
time frame: Within 30 days of study enrolment
description: Incidence of post-appointment IBD related hospital admission will be recorded for all patients enrolled in the study. Post-appointment hospital admissions will be defined as any IBD related hospital admission following the initial urgent care clinic appointment when the patient was enrolled in the study. Post-appointment IBD related hospital admission rates will will be compared between study groups.
measure: Post-Appointment IBD related Surgery
time frame: Within 30 days of study enrolment
description: Incidence of post-appointment IBD related surgery will be recorded for all patients enrolled in the study. Post-appointment IBD related surgery will be defined as any IBD related surgery following the initial urgent care clinic appointment when the patient was enrolled in the study. Post-appointment IBD related surgery rates will be compared between compared study groups
measure: Patient Satisfaction with Health Care in IBD
time frame: At 30 days following study enrolment
description: Patient satisfaction with health care in IBD as measured by CACHE will be collected from all patients, through a web-based questionnaire administered at 30 days following the initial urgent care clinic appointment, where the patient was enrolled in the study. Mean scores for Patient Satisfaction with Health Care in IBD will be compared between study groups.
measure: IBD related Quality of Life
time frame: At 30 days following study enrolment
description: IBD related Quality of Life as measured by IBDQ will be collected from all patients, through a web-based questionnaire administered at 30 days following the initial urgent care clinic appointment, where the patient was enrolled in the study. Mean scores for IBD related Quality of Life will be be compared between study groups.
measure: Disease Activity
time frame: At 30 days following study enrolment
description: Disease Activity as measured by PRO-2 score for Crohn's Disease or the 6-Point Mayo score for Ulcerative Colitis will be collected from all patients, through a web-based questionnaire administered at 30 days following the initial urgent care clinic appointment where the patient was enrolled in the study. Mean scores for disease activity will be compared between study groups.
arm group label: Telemedicine Follow-Up and Telemedicine Monitoring
arm group type: Experimental
arm group label: Minimal Intervention
arm group type: Active Comparator
intervention type: Behavioral
intervention name: Telemedicine Follow-Up
description: Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
arm group label: Telemedicine Follow-Up and Telemedicine Monitoring
intervention type: Other
intervention name: Telemedicine Monitoring
description: Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
arm group label: Telemedicine Follow-Up and Telemedicine Monitoring
intervention type: Behavioral
intervention name: 30 Day Comprehensive Questionnaire
description: Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
arm group label: Minimal Intervention
arm group label: Telemedicine Follow-Up and Telemedicine Monitoring
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Geoffrey C Nguyen
role: Principal Investigator
affiliation: MOUNT SINAI HOSPITAL
last name: Geoffrey C Nguyen, MD, PhD
phone: 416-586-4800
phone ext: 2819
email: geoff.nguyen@utoronto.ca
facility: 
contact: 
country: Canada
citation: Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, Glasgow KW, Fernandes A, Ghosh S. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012 Nov;26(11):811-7. doi: 10.1155/2012/984575.
PMID: 23166905
citation: Park MD, Bhattacharya J, Park K. Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting. PeerJ. 2014 Sep 23;2:e587. doi: 10.7717/peerj.587. eCollection 2014.
PMID: 25279267
citation: Novak K, Veldhuyzen Van Zanten S, Pendharkar SR. Improving access in gastroenterology: the single point of entry model for referrals. Can J Gastroenterol. 2013 Nov;27(11):633-5. doi: 10.1155/2013/519342. Epub 2013 Sep 13.
PMID: 24040629
citation: Paterson WG, Depew WT, Pare P, Petrunia D, Switzer C, Veldhuyzen van Zanten SJ, Daniels S; Canadian Association of Gastroenterology Wait Time Consensus Group. Canadian consensus on medically acceptable wait times for digestive health care. Can J Gastroenterol. 2006 Jun;20(6):411-23. doi: 10.1155/2006/343686.
PMID: 16779459
citation: Paterson WG, Barkun AN, Hopman WM, Leddin DJ, Pare P, Petrunia DM, Sewitch MJ, Switzer C, van Zanten SV. Wait times for gastroenterology consultation in Canada: the patients' perspective. Can J Gastroenterol. 2010 Jan;24(1):28-32. doi: 10.1155/2010/912970.
PMID: 20186353
citation: Cross RK, Kane S. Integration of Telemedicine Into Clinical Gastroenterology and Hepatology Practice. Clin Gastroenterol Hepatol. 2017 Feb;15(2):175-181. doi: 10.1016/j.cgh.2016.09.011. Epub 2016 Dec 16. No abstract available.
PMID: 27989663
citation: Kemp K, Griffiths J, Campbell S, Lovell K. An exploration of the follow-up up needs of patients with inflammatory bowel disease. J Crohns Colitis. 2013 Oct;7(9):e386-95. doi: 10.1016/j.crohns.2013.03.001. Epub 2013 Mar 27.
PMID: 23541150
responsible party type: Sponsor
mesh term: Crohn Disease
mesh term: Colitis
mesh term: Colitis, Ulcerative
mesh term: Intestinal Diseases
mesh term: Inflammatory Bowel Diseases
sharing ipd: No